



天 银

TIANYIN PHARMACEUTICAL CO., INC.

NYSE AMEX: TPI

December 2011

ir@tpi.asia

Safe Harbor Statement


Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth in this presentation that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, fluctuations in the economy, results of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Tianyin Pharmaceutical Inc.'s filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements contained in this presentation are made only of this date, and Tianyin Pharmaceutical Inc. is under no obligation to revise or update these forward-looking statements.

TPI, a growth story

| | 2003 | 2011 | Year | Book value (\$MM) |
|----------------|-------|-------|------|-------------------|
| Revenue (\$MM) | 0.4 | 95.2 | 2005 | 0.5 |
| Gross profit | 0.16 | 42.5 | 2006 | 3.3 |
| EBIT | (0.4) | 18.1 | 2007 | 12.0 |
| Net income | (0.4) | 14.0 | 2008 | 32.8 |
| Products | 7 | 58 | 2009 | 40.9 |
| Employees | 80 | 1,365 | 2010 | 62.3 |
| Facilities | 1 | 3 | 2011 | 80.8 |
| Cash | 0.4 | 31.7 | | |




TPI
Chengdu,
Sichuan
Province



Source: TPI historical data

TPI Sales (\$MM) growth by products (2005 – 2010)



Ginkgo Biloba, an introduction



2,771 publications up till 12/5/11 on Ginkgo

银杏 (Yin Xing) Ginkgo: (silver apricot)

Indications:


Neurological disorders, cardiovascular diseases, retinal deterioration

Major components of the leaf extracts:


Flavonoids and terpenoids. Flavonoids are composed of ginkgoflavone glycoside. Terpenoids are made of ginkgolides and bilobalide.

Mechanisms:

Flavonoids: potent antioxidant, reducing capillary fragility.
Terpenoids inhibit platelet activating factor (PAF).



Ginkgolides



Flavonoids

Science of Ginkgo

Effects of Ginkgo biloba extract on heart and liver mitochondrial functions: mechanism(s) of action.

Baliutyte G et al. J Bioenerg Biomembr. 2010 Apr;42(2):165-72. Epub 2010 Mar 19

Mild uncoupling activity of Ginkgo Biloba extracts provides pharmacological protection of cellular functions in pathological situations.

Kaempferol and quercetin, components of Ginkgo biloba extract (EGb 761), induce caspase-3 dependent apoptosis in oral cavity cancer cells.

Kang JW et al. Phytother Res. 2010 Jan;24 Suppl 1:S77-82

Kaempferol and quercetin, two components of EGb 761, effectively induce caspase-3-dependent apoptosis of oral cavity cancer cells and can be considered as anti-oral cavity cancer agents.

Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cells.

Shi C et al. Apoptosis. 2010 Mar 24

Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761).

Abdel-Kadera R et al. Pharmacological Research 56, 6, Dec 2007, 493-502

Fourteen day treatment with EGb 761 on aged mice group showed beneficial effects on mitochondrial complexes I, IV and V.

Mihuan

Armillaria mellea




Gastrodia elata



171 articles on *Gastrodia elata*


Anti-aging, memory enhancement, insomnia, immune system enhancement, lower blood pressure.

Sun, Y (2009) *China Geriatrics Journal*, 29: 899–901



> 250 subjects, 5 hospitals, $p < 0.02$

Source: TPI GMOL new drug application data series



National Drug Serial No. H20013079

Product name 银杏蜜环口服溶液


English name Yinxingmihuan Koufurongye

Company Chengdu Tianyin Pharmaceutical

Source: www.sfda.gov.cn

The Portfolio

- **58** products: modernized TCM products and branded generics
Lead product portfolio (5 year CAGR: 55%):
 - Ginkgo Mihuan Oral Liquid (GMOL) – Patented prescription biopharmaceutical
 - Azithromycin (AZI) – Essential Drug Listed highly effective antibiotic
 - Qing Re Jie Du Oral Liquid (QR) – Legacy anti-viral OTC medicine
 - Apu Shuangxin Benorylate Granules (APU) – Proprietary branded generic
 - Xuelian Chongcao Oral Liquid (XLCC) – Proprietary immunity enhancement
- **24** products listed in the National Medical Reimbursement List
- **7** drugs included in the Essential Drug List (EDL)
- **6** approvals from Chinese SFDA through FY2011
- **Performance:** FY2011 (6/30/11)
 - Revenue: \$95.2 MM
 - Net income: \$15.7 MM
- **FY2011 guidance**
 - Revenue: \$100.0 MM
 - Net income: \$11.0 MM



Manufacturing Facility

GMP certified plants: 3

Production lines: 7, oral, liquid, syrup, capsule, granules, tablets and compounds



Preparation

Raw materials purification for key ingredient selection, processing.

Extraction & Concentration

Multi-step extraction and concentration

Production and Packaging

Final products with different formulations: capsules, tablets, syrups, tinctures and granules

New capacity added in September 2009

| PRODUCTON LINES | PRE-EXPANSION CAPACITY | CURRENT CAPACITY |
|-----------------|------------------------|-------------------|
| Tablets | 600 million | 1500 million |
| Capsules | 200 million | 400 million |
| Granules | 50 million packs | 100 million packs |
| Liquid Solution | 120 million tubes | 120 million tubes |

Sales & Marketing



TPI sales & marketing national coverage

- **Three-pronged distribution channels covering over 900 hospitals nationwide in 200 medium to large cities**

Branded Proprietary Products,
Prescription Drugs, OTC products

- **Nationwide distribution network coverage**

Seasoned management and sales team
Strategic classification for each market segment

Prioritize resources for products based on their market potential

Emphasis on top tier hospitals and top tier cities

730 direct and indirect sales representatives targeting different market segments

Extensive nationwide distribution network covering essentially all geographical regions

OTC Customers



Jiangchuan Macrolide Facility (JCM)

- Jiangchuan Pharmaceutical: jointly owned by TPI (87%) and Mingxin Pharmaceutical Co., Ltd. (13%), to produce Active Pharmaceutical Ingredients (API) of macrolide antibiotics, capitalizing on price appreciation, favorable health care reform policy, and efficient profit chain/cash flow.
- Phase I: Oral and Injectable API for Azithromycin and other macrolide intermediaries, targeting 240 ton annual capacity, construction completed, GMP certification in progress
- Targeting \$30 million macrolide API revenue for JCM's first 12 months of operation
- Gross margin estimate: 25%, Net margin estimate: 10%



Income Statement

| Income Statement (\$ in MM) | FY2012 (9/30/11) | FY2011 (9/30/10) | FY2011 (6/30/11) | FY2010 (6/30/10) | FY2009 | FY2008 |
|--------------------------------|---------------------|---------------------|---------------------|---------------------|------------|------------|
| Sales | 17.5 | 22.0 | 95.2 | 63.9 | 42.9 | 33.5 |
| <i>Growth (YOY)</i> | <i>-20%</i> | <i>49%</i> | <i>56%</i> | <i>49%</i> | <i>28%</i> | <i>64%</i> |
| Cost of sales | 11.7 | 11.1 | 52.7 | 30.6 | 21.5 | 18.8 |
| Gross profit | 5.9 | 10.8 | 42.5 | 33.3 | 21.4 | 14.7 |
| <i>Gross margin</i> | <i>34%</i> | <i>49%</i> | <i>28%</i> | <i>52%</i> | <i>50%</i> | <i>44%</i> |
| Operating expenses | 3.7 | 6.2 | 24.4 | 18.6 | 11.7 | 7.1 |
| Operating profit | 2.1 | 4.6 | 19.7 | 14.5 | 9.7 | 7.6 |
| <i>Operating margin</i> | <i>12%</i> | <i>21%</i> | <i>20%</i> | <i>23%</i> | <i>23%</i> | <i>23%</i> |
| Provision for income taxes | 0.6 | 0.9 | 4.1 | 2.6 | 1.6 | 1.2 |
| Net income | 1.5 | 3.4 | 15.7 | 11.9 | 7.9 | 6.0 |
| <i>Growth (YOY)</i> | <i>-56%</i> | <i>58%</i> | <i>32%</i> | <i>52%</i> | <i>32%</i> | <i>4%</i> |

Balance Sheet

| Balance Sheet (\$ in MM) | 9/30/11 | 6/30/11 |
|---|-------------|-------------|
| Assets | | |
| Cash and cash equivalents | 34.8 | 31.7 |
| Accounts receivable | 8.8 | 9.0 |
| Inventory | 4.2 | 4.9 |
| Other current assets | 0.8 | 1.7 |
| Total current assets | 48.6 | 47.4 |
| Property and equipment, net | 27.7 | 27.5 |
| Intangibles, net | 17.9 | 15.3 |
| Total assets | 94.3 | 90.2 |
| Liabilities & Shareholders' Equity | | |
| Total Current Liabilities | 10.3 | 8.9 |
| Long-term liabilities (warrants) | - | - |
| Total Liabilities | 10.3 | 8.9 |
| Total Stockholders' Equity | 84.0 | 81.3 |
| Total Liabilities & Equity | 94.3 | 90.2 |

The Growth Ahead

- **Expanded capacity**
 - Additional products online after capacity expansion
 - Focus on higher margin, specialty products
- **Marketing and sales efforts**
 - Expand sales force and distribution channels
 - Develop current portfolio market penetration
 - Tianyin Medicine Trading (TMT) Distribution business development
 - New product launch
 - Focus on flagship products such as GMOL
- **R&D and pipeline**
 - R&D platform optimization
 - Partnership and in-licensing
- **Acquisition Opportunities**
 - Marketing and distribution network with complementary coverage
 - Manufacturing companies with complementary portfolio and patient population
- **Macrolide antibiotic initiative**
 - JCM, targeting \$30 million macrolide API revenue for the first 12 months operation

Management Team

- **Dr. Jiang, Guoqing M.D., Chairman & Chief Executive Officer**

Well-respected industry veteran with over 15 years of proven track record in pharmaceutical R&D, sales and modernized TCMs; served as President and CEO of Tianyin since 2003; Former CEO of Kelun Pharmaceutical Group (from 1996 through 2003) that is the leading producer in I.V. solution products with annual revenue over \$700 million and 7,000 employees; Graduated from Jiangsu University Medical School with a M.D. degree.

- **Dr. James J. Tong, MD, Ph.D., Chief Financial Officer, Chief Business Development Officer, Director**

Former Head of China Healthcare Investment Banking at ROTH Capital Partners; Former equity research analyst at ROTH, covering U.S.-listed pharmaceutical, biotech, medical devices, healthcare services and drug retail companies. in China. Former biotechnology analyst at Rodman & Renshaw, New York, covering biotech entities focusing on molecular diagnostics. Before Wall Street, Dr. Tong was Principal Investigator at Marine Biological Laboratory (MBL) sponsored by Grass Foundation at Woods Hole, MA and a Senior Research Fellow at University of California, Irvine (UCI); Awarded Ph.D. in Neurobiology and Behavior from Cold Spring Harbor Laboratory/Stony Brook University Neuroscience program; Published three first-authored Nature articles; Holds two patents; Medical degree from Peking University Health Science Center.

- **You, Xintao, Chief Technology Officer**

Oversees TPI's manufacturing, R&D, quality assurance, regulatory approval and operation; Over 20 years of industry experience including the successful R&D of GMOL, patent application and SFDA approvals; Former research scientist with the SFDA-affiliated Sichuan Industrial Institute of Antibiotics which is the largest antibiotics research institute in China; Former faculty member of West China School of Pharmacy at Sichuan University; Previously served as Director of Quality System at Sichuan Qili Pharmaceutical, the first Sino-US pharmaceutical joint-ventured company in Sichuan; Earned Master's degree in Pharmacy at China Pharmaceutical University and Sichuan University West China Center of Medical Sciences.

Management Team (continued)

- **Yang, Tao, Chief Operating Officer**

Well-known certified pharmaceutical sale training specialist with more than 18 years experience in sales and marketing industry; Former sales training specialist and marketing manager for Astra Zeneca and Bayer; managing the training services for 85 many well-known domestic and international pharmaceutical companies during the past ten years, including Grünenthal- San Huan Pharmaceutical (China) Co., Ltd., Beaufour Ipsen Pharmaceutical Co., Ltd., and Yangtze River Pharmacy Group, etc.; served as BPIP implementation consultant of CPDF launched by World Bank since 2001, and the executive advisor of a policy system program in 2007, which is a training system formed by the Chinese and British government aiming to support the domestic small to medium size businesses.

- **Dr. Zhang, Daqiao, Director of Sales**

Sales and marketing expert with over 15 years of experience; Previously served in various senior marketing and sales positions at Simcere Pharmaceutical Group (NYSE: SCR) and Nanjing Medical Company (SHSE: 600713); Graduated from Jiangsu University Medical School; Awarded MBA from Macau University of Sciences and Technology.

Independent Directors

- **Professor Zhang, Zunjian, Ph.D., Board Director**

Faculty advisor at China Pharmaceutical University, Executive Director at the Center for Instrument Analysis and in charge of the National Key Laboratory of Drug Quality Control at the university; member of the Chinese Pharmacopoeia Commission and a SFDA expert review committee member for new drugs and health food products; Expert review panel member at the National Center for Drug Pricing Evaluation and the SFDA, Jiangsu Province; Principal investigator in many national research projects and has published over 100 peer-reviewed research papers in prestigious journals both in the PRC and internationally.

- **Professor Hou, Jianping, Ph.D., Board Director**

Faculty advisor at Shaanxi University of Traditional Chinese Medicine; Principal investigator in more than 10 national research projects and has received the scientific achievement award from the State Administration of Traditional Chinese Medicine; SFDA expert review committee member for new drugs and health food products and an Executive Director at Shaanxi Pharmacological Society and the Clinical Pharmacology Committee of Shaanxi Pharmaceutical Association; Ph.D. in Pharmacology of Traditional Chinese Medicine from Beijing University; EMBA program for top pharmaceutical executives at Beijing University.

- **James T. McCubbin, Board Director, Audit Committee Chairman**

Vice President, Chief Financial Officer, and Director at WidePoint Corporation (AMEX: WYY); Held various senior financial management positions with several companies in the financial and government sectors; Director and chairman of the audit committee for Red Mile Entertainment, Inc., a developer, publisher, and licensor of interactive entertainment software.

Tianyin Pharmaceutical Co. Inc. (TPI)

NYSE Amex: TPI

Price (12/4/10): \$0.73

Shares Outstanding: 29.4 MM

Market Cap: \$21.4 MM

Management Ownership: 31%

FY2011 Results:

Revenue: \$95.2 MM ;

Net income: \$15.7 MM

Net margin: 16.5%

Diluted Shares (12/4/11): 29.4 MM


FY2012 Guidance:

Revenue: \$100 MM

Net income: \$11 MM

Auditor: Patrizio & Zhao, LLC

Legal: Hunter Taubman Weiss LLP



Investors Contact:
James J. Tong M.D. Ph.D.
Chief Financial Officer
Chief Business & Development Officer
Director

www.tianyinpharma.com

Dr.Tong@tpi.asia

Dr.Tong.TPI@gmail.com

+86 028 8551 6696 (Chengdu)

+86 134 36 550011 (China cell)

+949 350 6999 (U.S.)